ABSI
What one share of Absci holds
Services – Commercial Physical and Biological Research
We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop.
Absci’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.80 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.72 |
| Cash and investments | $1.17 |
| Debt | $0.01 |
| Book value | $1.43 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.31 | −$3.19 | $0.14 | −$0.85 | — | −$5.00 |
| 2021 | $0.10 | −$2.08 | $0.77 | −$1.99 | — | $3.95 |
| 2022 | $0.06 | −$1.15 | $0.18 | −$1.07 | — | $2.97 |
| 2023 | $0.06 | −$1.20 | $0.01 | −$0.71 | — | $1.89 |
| 2024 | $0.04 | −$0.94 | $0.00 | −$0.66 | — | $1.55 |
| 2025 | $0.02 | −$0.84 | $0.01 | −$0.69 | — | $1.24 |